Scarica l'app Stockscreener
3.34
3.75%
-0.13
Dopo l'orario di chiusura:
3.40
0.06
+1.80%
Precedente Chiudi:
$3.47
Aprire:
$3.44
Volume 24 ore:
107.66K
Relative Volume:
0.73
Capitalizzazione di mercato:
$126.12M
Reddito:
-
Utile/perdita netta:
$-27.66M
Rapporto P/E:
-3.5158
EPS:
-0.95
Flusso di cassa netto:
$-24.36M
1 W Prestazione:
+0.30%
1M Prestazione:
+13.61%
6M Prestazione:
-15.66%
1 anno Prestazione:
+73.96%
Intervallo 1D:
$3.30
$3.45
Intervallo di 1 settimana:
$3.30
$3.70
Portata 52W:
$1.60
$5.885
Genelux Corp Stock (GNLX) Company Profile
Nome
Genelux Corp
Settore
Industria
Telefono
805-267-9889
Indirizzo
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Confronta GNLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.34 | 131.03M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-29 | Iniziato | Guggenheim | Buy |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-11-27 | Iniziato | H.C. Wainwright | Buy |
| 2023-09-12 | Iniziato | Maxim Group | Buy |
| 2023-02-15 | Iniziato | The Benchmark Company | Speculative Buy |
Genelux Corp Borsa (GNLX) Ultime notizie
What drives Genelux Corporation stock priceBreakthrough investment results - Autocar Professional
Genelux Corporation Stock Analysis and ForecastTriple returns potential - Autocar Professional
Genelux stock maintains Buy rating at H.C. Wainwright amid sector news - Investing.com India
Genelux stock maintains Buy rating at H.C. Wainwright amid sector news By Investing.com - Investing.com South Africa
Promising Prospects for Genelux Corp.’s Olvi-Vec: A Buy Rating Based on Strong Clinical Trial Design and Efficacy - TipRanks
What analysts say about Genelux Corporation stockOutstanding risk-reward balance - jammulinksnews.com
Lucid Capital Initiates Coverage on Genelux with a Buy Rating, Setting a Price Target of $10. - AInvest
Lucid Capital Initiates Coverage of Genelux with Buy Rating and $10 Price Target - AInvest
Genelux: LUCID CAPITAL MARKETS Initiates Buy Coverage, PT $10 - AInvest
Lucid Capital Markets initiates Genelux stock with Buy rating, $10 target By Investing.com - Investing.com South Africa
Genelux initiated with a Buy at Lucid Capital - TipRanks
Is Genelux Corporation a good long term investmentExceptional portfolio growth - Autocar Professional
Genelux Corp: A Promising Investment in the Oncolytic Virus Space with Key Clinical Milestones Ahead - TipRanks
What risks could impact Genelux Corporation stock performanceExpert Trading Flow - Newser
Genelux Corporation (NASDAQ:GNLX) Position Trimmed by Stratos Wealth Partners LTD. - Defense World
Why Genelux Corporation stock attracts strong analyst attentionProven Win Setups - Newser
What makes Genelux Corporation stock price move sharplyFree VIP Investment Strategies - Newser
Genelux (NASDAQ:GNLX) Raised to “Hold” at Wall Street Zen - Defense World
Amgen Alum Takes Legal Reins of Biotech Firm Developing Cancer Treatment - Law.com
Genelux Appoints Groen as General Counsel From Rani Therapeutics - Bloomberg Law News
Biopharma Co. Genelux Hires Life Sciences Veteran As GC - Law360
Genelux appoints Eric Groen as general counsel, corporate secretary, CCO - TipRanks
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development - MarketScreener
Former Amgen $10B Deal Architect Joins Genelux Leadership to Drive Strategic Growth - Stock Titan
Genelux Corporation Appoints Eric Groen as General Counsel and Head of Business Development - Quiver Quantitative
Genelux Corporation (NASDAQ:GNLX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
June 2025's Promising Penny Stocks For Savvy Investors - simplywall.st
Two Sigma Investments LP Sells 18,446 Shares of Genelux Co. (NASDAQ:GNLX) - Defense World
Citadel Advisors LLC Lowers Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Millennium Management LLC Cuts Stake in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Co. (NASDAQ:GNLX) Shares Sold by Squarepoint Ops LLC - Defense World
Wall Street Zen Downgrades Genelux (NASDAQ:GNLX) to Sell - Defense World
Genelux Co. (NASDAQ:GNLX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Genelux (NASDAQ:GNLX) Trading Up 3.3% – Time to Buy? - Defense World
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Top Executives at Genelux Corp. Unload Thousands of Shares! - TipRanks
GENELUX Corp Executives Sell Shares to Cover Taxes - TradingView
Genelux Q3 EPS Raised by Brookline Capital Management - Defense World
HC Wainwright Issues Optimistic Outlook for Genelux Earnings - Defense World
Genelux Corp.’s Promising Prospects: Buy Rating Backed by Strong Phase 3 Trial and Financial Position - TipRanks
Genelux (GNLX) Price Target Lowered by Benchmark Analyst | GNLX Stock News - GuruFocus
Promising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating - TipRanks
H.C. Wainwright lifts Genelux stock target to $31, maintains buy By Investing.com - Investing.com Nigeria
H.C. Wainwright lifts Genelux stock target to $31, maintains buy - Investing.com
Genelux reports Q1 EPS (21c), consensus (24c) - TipRanks
Genelux (GNLX) Shows Strong Progress in Cancer Treatment Trials | GNLX Stock News - GuruFocus
Genelux Reports 71% Disease Control Rate in Lung Cancer Trial, Q1 2025 Earnings | GNLX Stock News - Stock Titan
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates - Yahoo Finance
Geode Capital Management LLC Has $716,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux CEO Discusses Next-Gen Immuno-Oncology Pipeline and Key Milestones at Citizens Conference - Stock Titan
LPL Financial LLC Has $222,000 Stock Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Corp Azioni (GNLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Genelux Corp Azioni (GNLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zindrick Thomas | President and CEO |
May 12 '25 |
Sale |
2.92 |
10,764 |
31,431 |
191,447 |
| Yu Yong | VP, Clinical Trial Operations |
May 12 '25 |
Sale |
2.92 |
5,579 |
16,291 |
47,640 |
| Cappello Joseph | VP, Pharmaceutical Development |
May 12 '25 |
Sale |
2.92 |
4,737 |
13,832 |
52,266 |
| Smalling Ralph | Head of Regulatory |
May 12 '25 |
Sale |
2.92 |
1,259 |
3,676 |
34,760 |
| Tyree James L | Director |
Dec 30 '24 |
Sale |
2.46 |
3,460 |
8,512 |
45,791 |
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):